GILD- Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 27 analysts
12-Month Price Target
$157.41
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $143.72
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$50.00
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
67% score
Pays dividends
11Y hist.11+ years of dividend history
Dividend consistency (5Y+)
11 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
-20.7%Return on equity - measures how efficiently capital is used
Positive profit margin
-10.6%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+10.2%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
223.47×Low financial leverage reduces risk of distress
Current ratio above 1
1.26×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$985M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.28%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 29, 2026
47
days
EPS (TTM)
$-2.64
P/E (TTM)
-
Fwd P/E
14.5
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.28%
5Y Avg Annual
$2.7600
Last Payment
$0.8200
Ex-Date
06/15/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest06/15/2026 | 06/29/2026 | $0.8200 | 2.28% |
03/13/2026 | 03/27/2026 | $0.8200 | 2.28% |
12/15/2025 | 12/29/2025 | $0.7900 | 2.20% |
09/15/2025 | 09/29/2025 | $0.7900 | 2.20% |
06/13/2025 | 06/27/2025 | $0.7900 | 2.20% |
03/14/2025 | 03/28/2025 | $0.7900 | 2.20% |
12/13/2024 | 12/27/2024 | $0.7700 | 2.14% |
09/13/2024 | 09/27/2024 | $0.7700 | 2.14% |
Magic Number
Shares needed to self-fund your next purchase
$143.72
Price
$0.8200
Last div. (quarterly)
176
shares
Own 176 GILD shares ($25,294.72) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$25,294.72
New shares / year
+4 shares
Dividend Calculator
2.28% yieldEstimate GILD dividend income at the current rate.
Per year
$228.22
Per month
$19.02
≈ 69.6 shares at $3.28/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
GILD vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Foster City, United States
Employees
17,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Gilead Sciences, Inc. (GILD) stock trades at $143.72, down 0.75% on the day. With a market capitalization of $178.21 billion, GILD is a large-cap healthcare stock. It trades at a forward P/E of 14.5 and earnings per share (EPS) of $-2.64. Over the most recent period the company reported 10% year-over-year revenue growth and a net profit margin of -10.6%. Below you'll find GILD's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
GILD - Frequently Asked Questions
Is Gilead Sciences, Inc. (GILD) a good stock to buy in 2026?
Gilead Sciences, Inc. (GILD) shows strengths such as revenue growth of 10%, while risks include negative profit margins and high leverage (debt/equity of 223.5). Whether GILD is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is GILD's stock price today?
Gilead Sciences, Inc. (GILD) trades at $143.72, down 0.75% on the session. Prices on this page update throughout the trading day.
Does GILD pay a dividend?
Yes. Gilead Sciences, Inc. pays an annual dividend of $3.28 per share, a dividend yield of 2.28%. The most recent ex-dividend date was September 15, 2026. Its payout ratio is about 43% of earnings.
What is GILD's market cap?
Gilead Sciences, Inc. (GILD) has a market capitalization of $178.21 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.